Global Market Size, Forecast, and Trend Highlights Over 2025-2037
Turner Syndrome Drug Market size is poised to witness over 7.8% CAGR during the forecast period i.e., between 2025-2037.
According to the National Library of Medicine in 2017, about 1 in every 2500 new-born girls, around the globe, were diagnosed with turner syndrome, making it one of the primary causes of female-fatal-miscarriages and stillbirths. According to report of National Institute of Health (NIH) U.S., the 45% of patients are affected with classic karyotype and the remaining 55% are affected with mosaic karyotype, a karyotype with abnormally in X chromosomes or may include Y chromosomes or its fragments. Besides, the female population increased from 3.6 billion in 2014 to 3.68 billion in 2016, according to the World Bank. Moreover, an increment of FDA approval for the treatment of the diseases along with the growing biotechnology sector and increasing awareness of women's health is expected to propel the growth of the market.
Turner Syndrome Drug Sector: Growth Drivers and Challenges
Growth Drivers
- Rising Awareness And Concerns For The Health of Women: A rise in patient awareness, prenatal genetic testing, healthcare awareness, and increase in investment in research and developments, and parents awareness and proactiveness towards their child’s health and willingness to seek a physician’s advice at an early stage are some factors that are expected to drive the turner syndrome market over the forecast period.
- Surge Inpatient Population To Boost The Turner Syndrome Drug Market: An increment in per capita income disposable income is uplifting people to spend more on healthcare facilities which play a vital role in the market. Varying demographics, as well as rapidly rising patients’ populations in appearing economies such as China, India, Brazil, and South Africa, are expected to thrust the growth of turner syndrome drug market over the forecast period.
Challenges
- Increasing concern for the expenditure on health and the rising annual expense on health treatment of individuals worldwide, coupled with the lack of awareness for the drug in several low and middle income nations are some of the factors anticipated to limit the growth of the global turner syndrome drug market in the coming years.
Turner Syndrome Drug Market: Key Insights
Turner Syndrome Drug Segmentation
The turner syndrome drug market is segmented by syndrome type, drug type, therapy type and by end-user. Among these segments, the end-user segment is further segmented to hospitals, homecare, specialty clinics, surgical centers and others, out of which, the segment of hospital is anticipated to hold the leading share in the market on account of availability of turner syndrome drugs used for the patient’s treatment only at the hospital. Global turner syndrome market is a highly disintegrated market and the major players have used various tactics such as joint ventures, partnerships, acquisitions, new product launches, expansion, agreement, and others to increase their mark in this market.
Our in-depth analysis of the global market includes the following segments
|
By Type |
|
|
By Drug Type |
|
|
By Therapy Type |
|
|
By End User |
|
Want to customize this research report as per your requirements? Our research team will cover the information you require to help you take effective business decisions.
Customize this ReportTurner Syndrome Drug Industry - Regional Synopsis
On the basis of regional analysis, the turner syndrome drug market is segmented into five major regions including North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa region.
North America industry is estimated to hold largest revenue share by 2037, on account of adoption of new technologies, existence developed economies, rising of healthcare expenditure and massive patient population. Europe holds the second-largest share in the market on account of rising research and development in the healthcare sector, mammoth patient population and growing biotechnology sector.
Companies Dominating the Turner Syndrome Drug Landscape
- Pfizer Inc.
- Company Overview
- Business Strategy
- Key Product Offerings
- Financial Performance
- Key Performance Indicators
- Risk Analysis
- Recent Development
- Regional Presence
- SWOT Analysis
- Novartis AG
- Bausch Health
- Johnson & Johnson Services Inc.
- Eli Lilly and Company
- F. Hoffmann-La Roche Ltd.
- Abbott Laboratories
- Merck & Co.
- Sanofi
- GlaxoSmithKline
In the News
- June 2020: The researchers at the Massachusetts General Hospital announced that they have identified a key mechanism in X chromosome inactivation. The released statement further stated that the phenomenon might hold clues that can lead to treatments for certain rare congenital disorders.
Author Credits: Radhika Pawar
- Report ID: 2640
- Published Date: Dec 23, 2024
- Report Format: PDF, PPT
